Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures

Bacterial Respiratory

Last Updated: September 1, 2014; Last Reviewed: September 1, 2014

Bacterial Respiratory Disease
Member Financial Disclosure
Company Relationship
Crothers, Kristina*
University of Washington None N/A
Miller, Robert University College London, England Gilead Honoraria, Speaker’s Bureau
Mark Allen Healthcare Honoraria
Merck Honoraria, Speaker’s Bureau
Moore, Matthew Centers for Disease Control and Prevention None N/A
Morris, Alison University of Pittsburgh Medical School Cape Cod Association Research Support
Gilead Research Support
NIH Research Support
Roche Research Support
Niederman, Michael Winthrop University Hospital Bayer Advisory Board, Honoraria, Research Support
Cubist Research Support
Merck Advisory Board
Pfizer Advisory Board, Honoraria

* Group lead

Note: Members were asked to disclose all relationships from 24 months prior to the updated date. The period of reporting was from September 1, 2012 through September 1, 2014.

Download Guidelines